Myeloperoxidase (MPO) is a peroxidase enzyme most abundantly present in neutrophil granulocytes (a subtype of white blood cells). It is a lysosomal protein stored in azurophilic granules of the neutrophil. MPO has a heme pigment, which causes its green color in secretions rich in neutrophils, such as pus and some forms of mucus.
Green tea is touted for its many health benefits as a powerful antioxidant, but experiments in a laboratory mouse model of inflammatory bowel disease suggest that consuming green tea along with dietary iron may actually lessen green tea's benefits.
Statins have been shown to reduce complications from cardiovascular surgery. To determine whether statins might also help those undergoing major lung surgeries, a team at Memorial Sloan Kettering Cancer Center conducted a well-designed study that randomized patients to receive either a statin or placebo before and after surgery.
Obese children who begin a low-fat, plant-based vegan diet may lower their risk of heart disease through improvements in their weight, blood pressure, body mass index, cholesterol levels, insulin sensitivity, and high-sensitivity C-reactive, according to Cleveland Clinic research published online today by The Journal of Pediatrics.
Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.
Even professional orchestra musicians suffer from particular stress on the day of the concert and release more cortisol.
A study has found functional and inflammatory changes in the nasal and lower airways of young, healthy smokers in the absence of pulmonary function decline.
A Loyola University Medical Center study suggests that a procedure to treat acid reflux could help prevent chronic rejection in lung transplant patients.
A research report appearing in the Journal of Leukocyte Biology helps explain how specific immune cells, called macrophages, accumulate triglycerides to support their function.
Scientists' discovery of an important step in the body's process for healing wounds may lead to a new way of treating inflammation.
Study findings show distinct subtypes of antineutrophil cytoplasmic antibody-associated vasculitis, distinguished by the target of autoantigen reactivity.
Cleveland HeartLab Inc. (CHL), a leading specialty clinical laboratory and disease management company, today announced the completion of an $18.4-million Series B financing round.
OXIS International, today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX joint health formula, launched commercially in December 2010.
OXIS International, Inc., today announced that is has filed a patent application titled "Methods and Compositions Using Ergothioneine to Treat a Variety of Health Related Factors" with the U.S. Patent and Trademark Office (USPTO).
OXIS International, Inc. announces the market launch of ErgoFlex™, a unique new dietary supplement for the relief of joint pain. It is the first in a series of commercial products planned by OXIS. ErgoFlex is the only joint health complex containing the powerful antioxidant Ergothioneine (ERGO), and is specifically formulated to help the body fight the pain of joint inflammation and maintain optimal joint health.
OXIS International, Inc., today announced that the "First International Congress on Ergothioneine, Anti-Oxidants, and Age Management Medicine" will be held Friday to Sunday, July 15-17, 2011, in the DeNeve Auditorium at the University of California, Los Angeles.
A new study reveals that two enzymes help immune cells deploy pathogen-killing traps by unraveling and using the chromatin (DNA and its associated proteins) contained in the cells' nuclei to form defensive webs. The study appears online on October 25 in The Journal of Cell Biology.
OXIS INTERNATIONAL, INC. and THE ESTEE LAUDER COMPANIES INC. announce today that they have resolved a dispute between an Estee Lauder subsidiary, Applied Genetics Incorporated Dermatics, and Oxis over technology related to U.S. Patent No. 6,103,746 and U.S. Patent No. 6,479,533, entitled "Methods and Compositions for the Protection of Mitochondria."
OXIS INTERNATIONAL, INC. is proud to announce that it has initiated active planning for the First World Congress on Ergothioneine, to be held in Los Angeles, California in July 2011 (the specific date will be announced at a later date).
OXIS INTERNATIONAL, INC. is proud to announce that it will introduce the benefits of Ergothioneine to the consumer market in September 2010 via breakthrough products for joint health and healthy aging. The first products, ErgoFlex® and ErgoPlex®, will initially be marketed via a direct mail offering being developed in partnership with Creative Direct Marketing Group, the leading service provider in the direct mail sector of the direct to consumer channel.
Discovery Laboratories, Inc., announced that new data regarding Surfaxin LS (its novel, lyophilized KL4 surfactant dosage form) were presented at the 2010 Pediatric Academic Societies Annual Meeting. The two studies presented demonstrate that Surfaxin LS improves lung function and oxygenation while attenuating lung inflammation in the preterm lamb model of respiratory distress syndrome.